All In Biotech

Drug Trial Radar · NCT05485961

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,110

Planned (sponsor's estimate)

Start

Apr 27, 2024

Primary completion

May 22, 2029

Study completion May 22, 2029

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Aug 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.

Conditions

  • End Stage Kidney Disease

Interventions

  • CSL300Drug

    IV administration

  • PlaceboDrug

    Matching the excipient content and concentration of the CSL300 product, minus the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline on the log scale in high-sensitivity C-reactive protein (hs-CRP)(Phase 2b)Time frame: Baseline and up to Week 12
  2. Time to first occurrence of CV death or myocardial infarction (MI) (Phase 3)Time frame: Approximately 5 years

Locations

566 sites in 35 countries. Site status is shown where the registry gives one.

  • Nephrology of North Alabama

    Decatur, Alabama · Recruiting

  • Nephrology Consultants, LLC

    Huntsville, Alabama · Recruiting

  • DaVita Clinical Research Montgomery

    Montgomery, Alabama · Recruiting

  • AKDHC Medical

    Glendale, Arizona · Recruiting

  • Kidney Disease Medical Group

    Glendale, Arizona · Recruiting

  • AKDHC Medical

    Phoenix, Arizona · Recruiting

  • AKDHC Medical

    Tucson, Arizona · Recruiting

  • Southern Arizona VA Health Care System

    Tucson, Arizona · Recruiting

  • National Institute of Clinical Research

    Bakersfield, California · Recruiting

  • Amicis Research Center

    Beverly Hills, California · Withdrawn

  • California Institute of Renal Research

    Chula Vista, California · Recruiting

  • The Medical Research Group, Inc.

    Fresno, California · Recruiting

  • Davita Fullerton Dialysis Center

    Fullerton, California · Recruiting

  • National Institute of Clinical Research, Inc.

    Fullerton, California · Recruiting

  • National Institute of Clinical Research, Inc.

    Garden Grove, California · Recruiting

  • St. Jude Medical Center

    Garden Grove, California · Recruiting

  • National Institute of Clinical Research

    Garden Grove, California · Recruiting

  • Sherman Medical Group, Inc

    Glendale, California · Recruiting

  • Kidney Disease Medical Group

    Glendale, California · Recruiting

  • Renal Consultants Medical Group

    Granada Hills, California · Recruiting

  • Balboa Research

    La Jolla, California · Recruiting

  • California Institute of Renal Research

    La Mesa, California · Recruiting

  • Southern California Medical Research Center

    La Palma, California · Recruiting

  • Academic Medical Research Institute

    Los Angeles, California · Recruiting

  • National Institute of Clinical Research, Inc.

    Los Angeles, California · Recruiting

  • DaVita Carabello Dialysis Center

    Los Angeles, California · Suspended

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Renal Medical Associates/NARI

    Lynwood, California · Recruiting

  • Amicis Research Center

    Northridge, California · Recruiting

  • FORMAT Medical Research

    Oxnard, California · Recruiting

  • National Institute of Clinical Research, Inc.

    Pomona, California · Recruiting

  • Van Buren Dialysis Center

    Riverside, California · Recruiting

  • National Nephrology Alliance Research - Riverside

    Riverside, California · Recruiting

  • Central Coast Nephrology Medical Corp

    Salinas, California · Recruiting

  • California Institute of Renal Research

    San Diego, California · Recruiting

  • California Institute of Renal Research

    San Diego, California · Suspended

  • North America Research Institute

    San Dimas, California · Recruiting

  • Satellite Healthcare

    San Jose, California · Suspended

  • Nephrology Educational Services

    Tarzana, California · Recruiting

  • Valiance Clinical Research

    Tarzana, California · Recruiting

Showing 40 of 566 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.